Regeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strength

EarningsDupixentEylea HDPositive

AI Analysis

Summary

Regeneron reported Q2 earnings that beat expectations, with sales growth driven by strength in Dupixent and Eylea HD. The company's key commercial products demonstrated continued market traction.

Outcome Details

Q2 earnings beat with sales up on Dupixent and Eylea HD strength

Importance:6/10

Sentiment:

0.70

earningsquarterly resultscommercial successpharma

Related Companies

$REGN

Read the original article

Published by yahoo_finance on July 30, 2026 3:58 PM

Read Original